

## **Appendix 1 (as submitted by the authors): Additional references**

### **References**

1. Dobkin, BH. What matters in cellular transplants for spinal cord injury: The cells, the rehabilitation, or the best mix? *Neurorehabil Neural Repair* 2010;24:7-9.
2. Iwatsuki K, Tajima F, Ohnishi Y, et al. A pilot clinical study of olfactory mucosa autograft for chronic complete spinal cord injury. *Neurol Med Chir (Tokyo)* 2016; 56:285-92.
3. Escada P, Capucho C, Pratas-Vital J, et al. Autograft-derived spinal cord mass. *J Neurosurg Spine* 2016;24:673-4.
4. Berkowitz AL, Miller MB, Mir SA, et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism.” *N Engl J Med* 2016;375:196-8.
5. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. *PLoS Med* 2009;6(2):e1000029.
6. Thirabanasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. *J Am Soc Nephrol* 2010;21:1218-22.